Skip to main content

To trade in the US, go to polymarket.us

icon for Eli Lilly licenses Peptron’s SmartDepot by October 7?
Tech·South Korea

Eli Lilly licenses Peptron’s SmartDepot by October 7?

icon for Eli Lilly licenses Peptron’s SmartDepot by October 7?
Tech·South Korea

Eli Lilly licenses Peptron’s SmartDepot by October 7?

13% chance
Polymarket

$11,314 Vol.

13% chance
Polymarket

$11,314 Vol.

This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”. Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify. Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify. The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.Eli Lilly’s non-exclusive evaluation agreement with Peptron for the SmartDepot sustained-release microsphere platform, extended through October 7, 2026, remains in the joint research phase with no commercial licensing or technology transfer announced. The 2024 deal allows Lilly to test SmartDepot’s ultrasonic spray-drying process for uniform PLGA microspheres and controlled release on peptide candidates, including GLP-1 assets and CNS programs, but explicitly stops short of granting commercial rights. Lilly’s separate 2025 licensing deal with Camurus for competing FluidCrystal technology in incretin therapies has added uncertainty around prioritization, while Peptron advances its own once-monthly semaglutide candidate PT403 independently. With the evaluation window closing in weeks and no binding agreement disclosed, trader consensus heavily favors resolution to “No.”

This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.

Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.

Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.

The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”. Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify. Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify. The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Volume
$11,314
End Date
Oct 7, 2026
Market Opened
May 5, 2026, 8:02 PM ET

Resolver

0x65070BE91...
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”. Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify. Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify. The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.Eli Lilly’s non-exclusive evaluation agreement with Peptron for the SmartDepot sustained-release microsphere platform, extended through October 7, 2026, remains in the joint research phase with no commercial licensing or technology transfer announced. The 2024 deal allows Lilly to test SmartDepot’s ultrasonic spray-drying process for uniform PLGA microspheres and controlled release on peptide candidates, including GLP-1 assets and CNS programs, but explicitly stops short of granting commercial rights. Lilly’s separate 2025 licensing deal with Camurus for competing FluidCrystal technology in incretin therapies has added uncertainty around prioritization, while Peptron advances its own once-monthly semaglutide candidate PT403 independently. With the evaluation window closing in weeks and no binding agreement disclosed, trader consensus heavily favors resolution to “No.”

This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.

Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.

Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.

The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”. Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify. Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify. The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Volume
$11,314
End Date
Oct 7, 2026
Market Opened
May 5, 2026, 8:02 PM ET

Resolver

0x65070BE91...

Related

icon for Skin cancer vaccine BLA submitted by June 30, 2027?

Skin cancer vaccine BLA submitted by June 30, 2027?

88%
icon for FDA approves Retatrutide this year?

FDA approves Retatrutide this year?

5%
icon for Skin cancer vaccine FDA approved by December 31, 2027?

Skin cancer vaccine FDA approved by December 31, 2027?

65%

Beware of external links.

Frequently Asked Questions

"Eli Lilly licenses Peptron’s SmartDepot by October 7?" is a prediction market on Polymarket where traders buy and sell "Yes" or "No" shares based on whether they believe this event will happen. The current crowd-sourced probability is 13% for "Yes." For example, if "Yes" is priced at 13¢, the market collectively assigns a 13% chance that this event will occur. These odds shift continuously as traders react to new developments and information. Shares in the correct outcome are redeemable for $1 each upon market resolution.

As of today, "Eli Lilly licenses Peptron’s SmartDepot by October 7?" has generated $11.3K in total trading volume since the market launched on May 5, 2026. This level of trading activity reflects strong engagement from the Polymarket community and helps ensure that the current odds are informed by a deep pool of market participants. You can track live price movements and trade on any outcome directly on this page.

To trade on "Eli Lilly licenses Peptron’s SmartDepot by October 7?," simply choose whether you believe the answer is "Yes" or "No." Each side has a current price that reflects the market's implied probability. Enter your amount and click "Trade." If you buy "Yes" shares and the outcome resolves as "Yes," each share pays out $1. If it resolves as "No," your "Yes" shares pay $0. You can also sell your shares at any time before resolution if you want to lock in a profit or cut a loss.

The current probability for "Eli Lilly licenses Peptron’s SmartDepot by October 7?" is 13% for "Yes." This means the Polymarket crowd currently believes there is a 13% chance that this event will occur. These odds update in real-time based on actual trades, providing a continuously updated signal of what the market expects to happen.

The resolution rules for "Eli Lilly licenses Peptron’s SmartDepot by October 7?" define exactly what needs to happen for each outcome to be declared a winner — including the official data sources used to determine the result. You can review the complete resolution criteria in the "Rules" section on this page above the comments. We recommend reading the rules carefully before trading, as they specify the precise conditions, edge cases, and sources that govern how this market is settled.